Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens.
Nicoletti P, Devarbhavi H, Goel A, Venkatesan R, Eapen CE, Grove JI, Zafer S, Bjornsson E, Lucena MI, Andrade RJ, Pirmohamed M, Wadelius M, Larrey D, Maitland-van der Zee AH, Ibanez L, Watkins PB, Daly AK, Aithal GP. Nicoletti P, et al. Among authors: larrey d. Clin Pharmacol Ther. 2021 Apr;109(4):1125-1135. doi: 10.1002/cpt.2100. Epub 2020 Dec 5. Clin Pharmacol Ther. 2021. PMID: 33135175 Free article.
Case definition and phenotype standardization in drug-induced liver injury.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Aithal GP, et al. Among authors: larrey d. Clin Pharmacol Ther. 2011 Jun;89(6):806-15. doi: 10.1038/clpt.2011.58. Epub 2011 May 4. Clin Pharmacol Ther. 2011. PMID: 21544079 Review.
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. Nicoletti P, et al. Among authors: larrey d. Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30. Gastroenterology. 2017. PMID: 28043905 Free PMC article.
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.
Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, Hallberg P, Li YJ, Lucena MI, Long N, Molokhia M, Nelson MR, Odin JA, Pirmohamed M, Rafnar T, Serrano J, Stefánsson K, Stolz A, Daly AK, Aithal GP, Watkins PB; Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). Cirulli ET, et al. Gastroenterology. 2019 May;156(6):1707-1716.e2. doi: 10.1053/j.gastro.2019.01.034. Epub 2019 Jan 18. Gastroenterology. 2019. PMID: 30664875 Free PMC article.
HLA associations with infliximab-induced liver injury.
Bruno CD, Fremd B, Church RJ, Daly AK, Aithal GP, Björnsson ES, Larrey D, Watkins PB, Chow CR. Bruno CD, et al. Among authors: larrey d. Pharmacogenomics J. 2020 Oct;20(5):681-686. doi: 10.1038/s41397-020-0159-0. Epub 2020 Feb 6. Pharmacogenomics J. 2020. PMID: 32024945
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.
Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium. Nicoletti P, et al. Pharmacogenet Genomics. 2016 May;26(5):218-24. doi: 10.1097/FPC.0000000000000209. Pharmacogenet Genomics. 2016. PMID: 26959717
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.
Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Ratziu V, et al. Among authors: larrey d. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12. Clin Gastroenterol Hepatol. 2014. PMID: 24530600 Clinical Trial.
Drug induced liver injury and vascular liver disease.
Larrey D, Meunier L, Valla D, Hillaire S, Hernandez-Gea V, Dutheil D, Plessier A, Bureau C. Larrey D, et al. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):471-479. doi: 10.1016/j.clinre.2020.03.020. Epub 2020 May 1. Clin Res Hepatol Gastroenterol. 2020. PMID: 32371005 No abstract available.
436 results